Dominique Koensgen | Semantic Scholar

Publications
Influence

Claim Your Author Page

Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications.

New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.

Jalid Sehouli, Dominique Koensgen, Guelten Oskay-Ozcelik, Alexander Mustea
Critical reviews in oncology/hematology
2008

Endometrial cancer is one of the most common gynaecological cancers in western countries. Most women are diagnosed at an early stage of the disease and can be cured by surgery alone. In patients with… (More)

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

Alexander Mustea, Dominique Koensgen, +11 authors Gabriele Koehler
Cancer Chemotherapy and Pharmacology
2013

PurposeThe management of high-risk endometrial cancer (HREC) remains controversial. We conducted a prospective multicenter phase-II clinical trial to evaluate an adjuvant chemotherapy (CT) with… (More)

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

Dominique Koensgen, Dirk Stengel, +11 authors on behalf of the Noggo Study Group Ovarian Cancer
Cancer Chemotherapy and Pharmacology
2007

ObjectiveSecond-line treatment with paclitaxel and carboplatin enhances survival of women with platinum-sensitive recurrent ovarian cancer (ROC). However, because of its cumulative neurotoxicity,… (More)

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study

Dominique Koensgen, Guelten Oskay-Oezcelik, +8 authors on behalf of the Nord-Ostdeutschen Gesellschaft für G life”
Supportive Care in Cancer
2009

Goals of workQuality of life (Qol) represents a relevant end point in the clinical management of advanced ovarian cancer (AOC). However, there exist only a few specific instruments which have been… (More)

Relapsed ovarian cancer after failure of first-line chemotherapy with platin and paclitaxel — a phase II study

Jalid Sehouli, Werner Lichtenegger, +7 authors Peter Ledwon
2001

Lebensqualität in der gynäkologischen Onkologie -Ein Bericht mit den Ergebnissen des ASCO-Meetings 2002

Jalid Sehouli, Dominique Koensgen, +6 authors Werner Lichtenegger
2003

Objective: Quality of Life (QoL) is increasingly relevant in the field of clinical research. Almost every clinical study analyses different aspects of QoL. The following summary discuss the question… (More)

P1-IS-41 Final results of a randomized multicenter phase III trial in 505 patients with relapsed ovarian cancer : topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine

Jalid Sehouli, Guelten Oskay-Oezcelik, +12 authors Werner Lichtenegger
2007

Comparison of laparoscopy-assisted vaginal hysterectomy as endoscopic single-station surgery and conventional laparoscopic hysterectomy—surgical effects on safety and quality of life

Alexander Mustea, Bernd Holthaus, +8 authors Dominique Koensgen
Gynecological Surgery
2019

BackgroundTo extend the benefits of minimally invasive surgery, an increasing enthusiasm has emerged for the laparo-endoscopic single-site surgery (LESS). The idea of LESS is to allow inserting… (More)

Dose-finding study of Topotecan (T) plus Carboplatin (C) for patients with platinum sensitive Relapsed Ovarian Cancer (ROC)

Dominique Koensgen, Antje Belau, +4 authors Jalid Sehouli
2006

Gynecologic oncology

G. Oskav-Özcelik, H. J. Hindenburg, +214 authors Sahin Zeteroğlu
Archives of Gynecology and Obstetrics
2005

OBJECTIVES: Caelyx is a novel pegylated liposomal doxorubicin formulation and has been approved for the treatment of recurrent ovarian cancer. METHODS: We performed a multi-institutional phase-II… (More)